Breaking Down the TRAILBLAZER-ALZ 2 Trial
Psychopharmacology and Psychiatry Updates · Psychopharmacology Institute
March 27, 202510m 27s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression?
Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D.